Jon laying the foundations here for future company success and strategically playing the long game.
I’d speculate that if NNZ-2591 proved successful in HIE for newborns, then naturally clinical trial attention would turn to the other large addressable market being non-newborns and adults suffering from HIE caused by cardiac arrest, stroke, respiratory failure, drowning, suffocation, and carbon monoxide poisoning.
Great to have some positive news today. Whether the share price reacts accordingly is an entirely different matter.
Jon laying the foundations here for future company success and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.29 |
Change
0.660(3.97%) |
Mkt cap ! $2.178B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $17.34 | $16.63 | $9.078M | 529.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1334 | $17.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.33 | 2245 | 3 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |